These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30406175)

  • 21. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum.
    Milà-Alomà M; Salvadó G; Gispert JD; Vilor-Tejedor N; Grau-Rivera O; Sala-Vila A; Sánchez-Benavides G; Arenaza-Urquijo EM; Crous-Bou M; González-de-Echávarri JM; Minguillon C; Fauria K; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Suárez-Calvet M; Molinuevo JL;
    Alzheimers Dement; 2020 Oct; 16(10):1358-1371. PubMed ID: 32573951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Millipore xMap® Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer's Biomarkers in Cerebrospinal Fluid.
    Hansen EO; Dias NS; Burgos ICB; Costa MV; Carvalho AT; Teixeira AL; Barbosa IG; Santos LAV; Rosa DVF; Ribeiro AJF; Viana BM; Bicalho MAC
    Front Psychiatry; 2021; 12():716686. PubMed ID: 34531769
    [No Abstract]   [Full Text] [Related]  

  • 23. Alzheimer's disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C.
    Konen FF; Maier HB; Neyazi A; Bleich S; Neumann K; Skripuletz T
    Neurol Res Pract; 2023 Jun; 5(1):30. PubMed ID: 37381021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CSF biomarkers for early-onset Alzheimer's disease in Chinese population from PUMCH dementia cohort.
    Lei D; Mao C; Li J; Huang X; Sha L; Liu C; Dong L; Xu Q; Gao J
    Front Neurol; 2022; 13():1030019. PubMed ID: 36698871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status.
    Kaplow J; Vandijck M; Gray J; Kanekiyo M; Huyck E; Traynham CJ; Esquivel R; Fagan AM; Luthman J
    Alzheimers Dement; 2020 Jan; 16(1):144-152. PubMed ID: 31914216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.
    Álvarez I; Aguilar M; González JM; Ysamat M; Lorenzo-Bosquet C; Alonso A; Tartari JP; Romero S; Diez-Fairen M; Carcel M; Pujalte F; Pastor P
    J Alzheimers Dis; 2018; 61(1):135-143. PubMed ID: 29154286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine.
    Chiasserini D; Biscetti L; Farotti L; Eusebi P; Salvadori N; Lisetti V; Baschieri F; Chipi E; Frattini G; Stoops E; Vanderstichele H; Calabresi P; Parnetti L
    J Alzheimers Dis; 2016 Jul; 54(1):55-67. PubMed ID: 27447425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings.
    Blennow K; Zetterberg H
    Prog Mol Biol Transl Sci; 2019; 168():3-23. PubMed ID: 31699324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging.
    Mo Y; Stromswold J; Wilson K; Holder D; Sur C; Laterza O; Savage MJ; Struyk A; Scheltens P; Teunissen CE; Burke J; Macaulay SL; Bråthen G; Sando SB; White LR; Weiss C; Cowes A; Bush MM; DeSilva G; Darby DG; Rainey-Smith SR; Surls J; Sagini E; Tanen M; Altman A; Luthman J; Egan MF
    Alzheimers Dement (Amst); 2017; 6():201-209. PubMed ID: 28349119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease.
    Pan C; Korff A; Galasko D; Ginghina C; Peskind E; Li G; Quinn J; Montine TJ; Cain K; Shi M; Zhang J
    J Alzheimers Dis; 2015; 45(3):709-19. PubMed ID: 25613100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort.
    Zwan M; van Harten A; Ossenkoppele R; Bouwman F; Teunissen C; Adriaanse S; Lammertsma A; Scheltens P; van Berckel B; van der Flier W
    J Alzheimers Dis; 2014; 41(3):801-7. PubMed ID: 24705549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes.
    van Waalwijk van Doorn LJ; Gispert JD; Kuiperij HB; Claassen JA; Arighi A; Baldeiras I; Blennow K; Bozzali M; Castelo-Branco M; Cavedo E; Emek-Savaş DD; Eren E; Eusebi P; Farotti L; Fenoglio C; Ormaechea JF; Freund-Levi Y; Frisoni GB; Galimberti D; Genc S; Greco V; Hampel H; Herukka SK; Liu Y; Lladó A; Lleó A; Nobili FM; Oguz KK; Parnetti L; Pereira J; Picco A; Pikkarainen M; de Oliveira CR; Saka E; Salvadori N; Sanchez-Valle R; Santana I; Scarpini E; Scheltens P; Soininen H; Tarducci R; Teunissen C; Tsolaki M; Urbani A; Vilaplana E; Visser PJ; Wallin AK; Yener G; Molinuevo JL; Meulenbroek O; Verbeek MM
    J Alzheimers Dis; 2017; 56(2):543-555. PubMed ID: 28059783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease.
    Delmotte K; Schaeverbeke J; Poesen K; Vandenberghe R
    Alzheimers Res Ther; 2021 Apr; 13(1):84. PubMed ID: 33879243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer's Disease.
    Almdahl IS; Lauridsen C; Selnes P; Kalheim LF; Coello C; Gajdzik B; Møller I; Wettergreen M; Grambaite R; Bjørnerud A; Bråthen G; Sando SB; White LR; Fladby T
    Front Aging Neurosci; 2017; 9():9. PubMed ID: 28223932
    [No Abstract]   [Full Text] [Related]  

  • 36. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
    Olsson B; Lautner R; Andreasson U; Öhrfelt A; Portelius E; Bjerke M; Hölttä M; Rosén C; Olsson C; Strobel G; Wu E; Dakin K; Petzold M; Blennow K; Zetterberg H
    Lancet Neurol; 2016 Jun; 15(7):673-684. PubMed ID: 27068280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Commutability of the certified reference materials for the standardization of β-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β-amyloid 1-40 measurements.
    Andreasson U; Kuhlmann J; Pannee J; Umek RM; Stoops E; Vanderstichele H; Matzen A; Vandijck M; Dauwe M; Leinenbach A; Rutz S; Portelius E; Zegers I; Zetterberg H; Blennow K
    Clin Chem Lab Med; 2018 Nov; 56(12):2058-2066. PubMed ID: 29949507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Two Analytical Platforms in Cerebrospinal Fluid Biomarkers for the Classification of Alzheimer's Disease Spectrum with Amyloid PET Imaging.
    Lim HJ; Park JE; Kim BC; Choi SM; Song MK; Cho SH; Seo HJ; Kim J; Song HC; Choi KY; Lee JJ; Kim HW; Ha JM; Song WK; Park SG; Lee JS; Lee KH
    J Alzheimers Dis; 2020; 75(3):949-958. PubMed ID: 32390627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.